fda compounding restrictions bpc-157 A step towards expanded patient access. This will allow patients to have conversations about these compounds in the clinical setting instead of resorting to a gray market without practitioner oversight or monitoring! BREAKING: The FDA just reversed

BREAKING: The FDA just reversed theIR 2023 peptide ban. 12 peptides were just pulled from the Category 2 restricted list: 1. BPC 157 2. Thymosin beta 4 fragment (TB 500) 3. Epitalon 4. GHK Cu (injectable) An FDA advisory committee voted Thursday to remove compounding restrictions on four peptides despite little evidence the products are safe or effective for medical use. In a series of 8 6 votes (with BPC 157 just got voted in favor to be added to the 503A Bulk Drug Substances list, meaning a huge step towards being able to be prescribed and compounded in the US. Thank FDA Panel Votes to Recommend BPC 157 for Pharmacy Compounding HealingMaps

SKU: 7346250918 · From clintoncounty708.com